CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium.

被引：0
|
作者：
Margolin, KA
Longmate, J
Baratta, T
Synold, T
Weber, J
Gajewski, T
Quirt, I
Christensen, S
Doroshow, JH
机构：
[1] Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA
[2] Univ Chicago, Sch Med, Chicago, IL 60637 USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Calif Davis, Sacramento, CA 95817 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页码：715S / 715S
页数：1
相关论文
共 50 条
  • [1] CCI-779 in metastatic melanoma - A phase II trial of the California Cancer Consortium
    Margolin, K
    Longmate, J
    Baratta, T
    Synold, T
    Christensen, S
    Weber, J
    Gajewski, T
    Quirt, I
    Doroshow, JH
    CANCER, 2005, 104 (05) : 1045 - 1048
  • [2] Molecular inhibition of mTOR with temsirolimus (TORISEL™, CCI-779) is a promising strategy in relapsed NHL:: The University of Chicago phase II consortium.
    Smith, Sonali M.
    Pro, Barbara
    Smith, Scott
    Stiff, Patrick
    Lester, Eric
    Modi, Sanjiv
    van Besien, Koen
    BLOOD, 2006, 108 (11) : 703A - 704A
  • [3] NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM).
    Galanis, E
    Buckner, JC
    Maurer, M
    Ballman, K
    Hidalgo, M
    Kreisberg, JI
    Boni, J
    James, CDD
    Jenkins, RB
    Walsh, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 107S - 107S
  • [4] A Phase II study of Temsirolimus (CCI-779) in patients with metastatic and/or recurrent endometrial cancer - NCICCTG IND 160
    Oza, A. M.
    Elit, L.
    Biagi, J.
    Panasci, L.
    Tonkin, K.
    Tsao, M.
    Dore, N.
    Dancey, J.
    Eisenhauer, E.
    Seymour, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 261
  • [5] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Chang, SM
    Wen, P
    Cloughesy, T
    Greenberg, H
    Schiff, D
    Conrad, C
    Fink, K
    Robins, HI
    De Angelis, L
    Raizer, J
    Hess, K
    Aldape, K
    Lamborn, KR
    Kuhn, J
    Dancey, J
    Prados, MD
    INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) : 357 - 361
  • [6] Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M. Chang
    Patrick Wen
    Timothy Cloughesy
    Harry Greenberg
    David Schiff
    Charles Conrad
    Karen Fink
    H. Ian Robins
    Lisa De Angelis
    Jeffrey Raizer
    Kenneth Hess
    Ken Aldape
    Kathleen R. Lamborn
    John Kuhn
    Janet Dancey
    Michael D. Prados
    Investigational New Drugs, 2005, 23 : 357 - 361
  • [7] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
    Galanis, E
    Buckner, JC
    Maurer, MJ
    Kreisberg, JL
    Ballman, K
    Boni, J
    Peralba, JM
    Jenkins, RB
    Dakhil, SR
    Morton, RF
    Jaeckle, KA
    Scheithauer, BW
    Dancey, J
    Hidalgo, M
    Walsh, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
  • [8] Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium
    Margolin, K
    Longmate, J
    Synold, TW
    Gandara, DR
    Weber, J
    Gonzalez, R
    Johansen, MJ
    Newman, R
    Baratta, T
    Doroshow, JH
    INVESTIGATIONAL NEW DRUGS, 2001, 19 (04) : 335 - 340
  • [9] Dolastatin-10 in Metastatic Melanoma: A Phase II and Pharmokinetic Trial of the California Cancer Consortium
    Kim Margolin
    Jeffrey Longmate
    Timothy W. Synold
    David R. Gandara
    Jeffrey Weber
    Rene Gonzalez
    Mary J. Johansen
    Robert Newman
    Tracey Baratta
    James H. Doroshow
    Investigational New Drugs, 2001, 19 : 335 - 340
  • [10] Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma
    Hofmeister, Craig C.
    Benson, Don
    Efebera, Yvonne A.
    Farag, Sherif
    Grever, Michael R.
    BLOOD, 2009, 114 (22) : 1126 - 1126
12345